Close Menu

FIND

The WHO and FIND are supporting NGS-based testing in low-resource settings, while a resistance testing program at New York State's Wadsworth Center has matured.

The firm launched a CE-IVD marked test for extremely drug-resistant TB and expects to incorporate the multiplexing technology in other assays.

FIND will use the funding to support the development of rapid tests, especially in low- and middle-income countries.

The Foundation for Innovative New Diagnostics is tracking commercial coronavirus diagnostics development project, with the goal of guiding procurement.

The two organizations are collaborating to perform a standardized evaluation of currently available molecular diagnostic tests to assess test performance.

FIND also announced support for projects from Axxin and DNC Dx for point-of-care detection of sexually transmitted infections.  

The project, called Seq&Treat, will be implemented in Brazil, China, Georgia, India, and South Africa starting in October.

The test for P. vivax-associated malaria was developed with support from FIND and will be distributed by Human Diagnostics Worldwide.

The firm has been placing point-of-care systems primarily in the private sector, but may have increased access once it completes WHO prequalification review.

FIND will lead evaluation studies in Cameroon and Georgia between September 2018 and May 2019 to confirm the assay's diagnostic accuracy and commercial utility.

Pages

The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.

According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.

The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.

In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.